YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
SAN FRANCISCO, October 08, 2026--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-ce…
– PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanced bladder cancer – – VYLOY™ (zolbetuximab) research reinforces the role of CLDN18.2 in shaping gastric cancer treatment decisions – TOKYO,…
Statistically significant improvements in bothersome VMS as well as sleep quality were observed at week 12, and also seen at weeks 4 and 8, among women treated with fezolinetant1 First real-world objective sleep outcomes data demonstrate f…
This article first appeared on GuruFocus. Evaluating the Sustainability of Astellas Pharma's Upcoming Payout Astellas Pharma Inc (ALPMF) recently announced a total dividend of $0.25 per share, with the ex-dividend date set for 2026-09-29.…
-Experienced biopharmaceutical executive brings decades of leadership in corporate strategy, finance and business development to support ARTHEx's next phase of growth- VALENCIA, Spain, Sept. 29, 2026 /PRNewswire/ -- Arthex Biotech, a clini…
Astellas Pharma shares have quietly built a strong track record, which raises a simple question for anyone looking at the stock today. Are the current cash flows of Astellas Pharma, and what investors expect them to deliver over time, enou…
Astellas Pharma CEO Naoki Okamura and 2375 Waterview Drive (Astellas, Transwestern) Astellas Pharmaceutical is testing the waters of the suburban Chicago office market by putting its office complex in Northbrook up for sale. Japan-based As…
- Study evaluates novel, investigational KRAS G12D-targeted protein degrader setidegrasib versus docetaxel in previously treated patients with advanced NSCLC - - Milestone marks second Phase 3 study of setidegrasib initiated within six mon…
Wall Street's major market averages finished lower on Friday after traders and investors digested the latest jobs data, which came in stronger than forecasted. The blue-chip Dow ended 0.5% lower, the benchmark S&P 500 slipped 0.3%, and the…
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. President Donald Trump has secured new drug pricing agreements with nine pharmaceutical companies, with an aim to align the prices of drug…
On Monday, President Trump announced that his administration has signed separate drug-pricing agreements with nine mid-sized pharmaceutical companies to lower drug prices in the country. These companies include Alcon, Astellas Pharma ALPMY…
[New York City and London multiple exposure image] Stock index futures pointed to a weaker open on Tuesday, setting Wall Street up for a lower start to September as investors monitored renewed tensions in the Middle East. Here are the five…
[Inspecting capsules before production] Dejan Sarec/iStock via Getty Images U.S. President Donald Trump introduced a new set of drug-pricing deals with global pharmaceutical companies and smaller biotechs on Monday, advancing efforts to cu…
– Agreement supports commitment to patient access, affordability and innovation – TOKYO, Aug. 31, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has reached an ag…
The nine drug companies committed to collectively invest at least $19.6 billion in U.S. manufacturing in the near term. Continue Reading
(Bloomberg) -- The Trump administration has struck new drug pricing agreements with nine biotech and pharmaceutical companies including UCB SA, Bridgebio Pharma Inc. and Sun Pharmaceutical Industries Ltd. Most Read from Bloomberg Nvidia to…
Astellas Pharma (TSE:4503) has started dosing the first patient in a Phase 3 trial of ASP2138 for CLDN18.2-positive and HER2-negative advanced gastric and gastroesophageal junction adenocarcinoma. The study focuses on a patient group with…
- ASP2138's advancement into Phase 3 marks an important milestone in Astellas' commitment to advancing research in CLDN18.2 with its differentiated portfolio, spanning approved treatments and investigational assets - TOKYO, Aug. 24, 2026 /…
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Aisin Seiki ASEKY is engaged in the manufacture and sale of automotive parts. The Zacks Consensus Estimate for its current year earnings has been revised almost 10.…
Company Logo Opportunities center on frontline immunotherapy combinations, biomarker and companion diagnostics, AI-enabled pathology, minimally invasive screening, precision therapies for uterine sarcomas, and tele-oncology expansion in un…
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Coinbase Global, Inc. COIN is an operator of crypto platforms. The Zacks Consensus Estimate for its current year earnings has been revised 81.6% downward over the l…
* Astellas Pharma ADR press release [https://www.astellas.com/content/dam/astellas-com/global/en/confidential-documents/financial-results/1q2026_en.pdf] (ALPMY [https://seekingalpha.com/symbol/ALPMY]): Q1 GAAP EPS of ¥78.96. * Revenue of ¥…
[Moscow, Russia - April 7, 2019: NVIDIA video chip on the motherboard] Antonio Bordunovi/iStock Editorial via Getty Images Nvidia (NVDA [https://seekingalpha.com/symbol/NVDA]) on Wednesday unveiled a broad slate of AI products, partnership…
Pfizer Inc. (NYSE:PFE) is one of the 8 Worst Blue Chip Stocks to Buy Now. On July 10, 2026, Pfizer Inc. (NYSE:PFE) and Astellas Pharma (ALPMY) announced that the U.S. Food and Drug Administration approved PADCEV, a Nectin-4 directed antibo…
Pfizer's (PFE) second-quarter revenue is expected to match Wall Street's estimates, while its earnin PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
First and only treatment regimen for adults with MIBC, regardless of cisplatin eligibility, representing a platinum-free potential standard of care Broadened approval supported by Phase 3 EV-304 data showing a nearly 50% reduction in the r…
[US Food and Drug Administration (FDA)] * The U.S. Food and Drug Administration on Friday approved a label expansion for a drug regimen combining Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) and Astellas’ (ALPMF [https://seekingalpha…
Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.4% and the State S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Sangamo Therapeutics, Inc. Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders Lilly and Astellas to serve as "stalking horse" bidd…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Astellas Pharma Inc. (ALPMY) is a stock that can certainly grab the attention of many investors, but do its recent returns…
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growt…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Internal overhaul and KRAS trial move Astellas into investor focus…
Ironwood Pharmaceuticals’ IRWD sole marketed product, Linzess (linaclotide), has witnessed a strong uptake in recent times. The company has a partnership with AbbVie ABBV to jointly develop and commercialize Linzess in the United States. L…
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to…
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Astellas Pharma Inc. (ALPMY) one of those stocks right now? A quick glance at the company's year-to-…
Ocugen OCGN is pushing three eye gene therapy programs toward late-stage regulatory timelines, setting up a catalyst-heavy stretch in 2026 and 2027. That opportunity comes with familiar biotech trade-offs. The company has no approved produ…